ulcerative colitis
Conditions
Interventions
None listed
Sponsors
Kyorin Pharmaceutical Co.,Ltd
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Outpatients 2) Adult patients who have been diagnosed with mild to moderate active ulcerative colitis or ulcerative colitis in the remission stage according to the diagnostic criteria for ulcerative colitis (draft revised on February 13, 2010) 3) Patients who have been treated with remission induction therapy or remission maintenance therapy with oral 5-ASA drugs (Pentasa® tablets 250 mg, Pentasa® tablets 500 mg, Asacol® tablets 400 mg and Salazopyrin® tablets 500 mg as well as drugs that have been proved equivalent to these drugs) 4) Patients who have received adequate information regarding this study and understood thoroughly, and then voluntarily submitted written consent forms upon participation in this study
Exclusion criteria
Exclusion criteria: 1) Patients with severe active ulcerative / fulminant ulcerative colitis according to the diagnostic criteria for ulcerative colitis (draft revised on February 13, 2012) 2) Patients who have received total / subtotal colectomy 3) Patients who have been complicated with malignant tumor 4) Patients who are pregnant or possibly pregnant 5) Other patients whom investigators and subinvestigators considered inappropriate to participate in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cumulative non-relapse rate | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Number of relapses 2)Duration of remission maintained (days) 3)The pUCDAI scores and the scores that constitute these pUCDAI scores at each assessment period 4)Medication adherence | — |
Countries
Japan
Contacts
Public ContactMichiaki Ota
Kyorin Pharmaceutical Co.,Ltd Medical Affairs
Outcome results
None listed